Shigella

vials vaccine research vaccines factory manufacturing

Valneva pays LimmaTech $10M for clinical-stage Shigella vaccine

Valenva added to its growing arsenal of vaccines by handing over 10 million euros for a Shigella candidate that once formed part of a GSK partnership.

James Waldron Aug 1, 2024 8:26am

LimmaTech regains shigella shot from GSK, new CEO from CureVac

Jul 20, 2023 10:31am